Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma

Recent clinical trials of lung adenocarcinoma with immune checkpoint inhibitors revealed that lung adenocarcinoma patients with EGFR mutations have a poor response to immunotherapy. However, the mechanisms have not been addressed. We performed immunohistochemistry analyses of resected lung adenocarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jia-Wei, Guo, Yan-Hua, Wu, Feng-Ying, Li, Xue-Fei, Sun, Xue-Cheng, Wang, Jia-Lu, Zhou, Cai-Cun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416409/
https://www.ncbi.nlm.nih.gov/pubmed/34484468
http://dx.doi.org/10.1155/2021/3776854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416409/
https://www.ncbi.nlm.nih.gov/pubmed/34484468
http://dx.doi.org/10.1155/2021/3776854

Ejemplares similares